GlassScriptPhysician profile
Joseph Iwuajoku
NPI 1922397876
$3,951.48
in general payments reported to CMS, 2019-2025
16 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $186 · 2023: $1,640 · 2024: $541 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Travel and Lodging: $950 · Honoraria: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.52 |
| Travel and Lodging | $949.95 |
| Honoraria | $285.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,332.60 | 2023 | Myfembree |
| Novartis Pharmaceuticals Corporation | $778.91 | 2022-2025 | |
| Exact Sciences Corporation | $418.99 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $311.97 | 2021-2025 | Mounjaro, Zepbound |
| Cipher Pharmaceuticals US LLC | $285.42 | 2025 | Natroba, Spinosad |
| Pfizer INC. | $192.73 | 2024-2025 | |
| Novo Nordisk INC | $154.29 | 2025 | Rybelsus, Ozempic |
| Hologic Sales and Service, LLC | $125.26 | 2023-2025 | Aptima, Thinprep 2000 Processor |
| Gilead Sciences, INC. | $85.44 | 2021 | |
| Exeltis, USA INC. | $66.14 | 2022-2023 | Nuvessa, Slynd |
| Sanofi Pasteur INC. | $45.48 | 2022 | |
| Boston Scientific Corporation | $42.55 | 2025 | Wavewriter Alpha Prime 16 |
| Shield Therapeutics INC | $31.74 | 2025 | |
| Genentech USA, INC. | $31.36 | 2021 | |
| Seqirus USA INC | $25.33 | 2025 | Fluad |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $23.27 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Iwuajoku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.